Redondo Beach

Researchers are evaluating Corabotase also known as IPN10200 to assess its effectiveness and safety compared to a placebo for improving the appearance of moderate to severe glabellar lines, which are wrinkle-like lines between the eyebrows. These lines can become more noticeable with age or repeated facial expressions and may affect a persons confidence. This Phase III, multicenter, randomized, double-blind study aims to measure treatment response and participant satisfaction. Participants will be randomly assigned to receive a single injection of either Corabotase or placebo into the muscles between the eyebrows during one treatment visit on Day 1. The study includes a screening period up to 20 days to determine eligibility, followed by the treatment day and a 52-week follow-up period. During follow-up, participants will have regular visits and one phone call to monitor their health and treatment effects. Throughout the study, participants will undergo physical exams, blood tests, heart electrical activity recordings ECG, clinical evaluations, questionnaires, and keep a diary. The research team will measure improvement in glabellar lines at various time points up to one year, along with participant satisfaction and safety events. Participants may withdraw from the study at any time, and the total participation lasts up to 55 weeks.

This research aims to evaluate the safety and effectiveness of ELAPR002f injectable gel in adults with moderate to severe atrophic acne scars. These scars are flat or indented marks that remain after acne heals and can affect quality of life through reduced self-esteem and embarrassment. The study is a controlled, randomized trial including about 395 adults with scarring on both cheeks, conducted at multiple sites in the United States. Participants are divided into two cohorts. Cohort 1 receives ELAPR002f injectable gel openly, while Cohort 2 participants are randomly assigned to receive either ELAPR002f gel or a saline control via intradermal injections. Treatments are given on Days 1, 31, and 61. After the three treatment sessions over two months, participants are followed for up to 12 months to observe outcomes and any side effects. During the study, participants will have regular visits at a clinic or hospital for medical assessments, blood tests, and questionnaires to monitor their progress and any side effects. Researchers will measure the percentage of participants who achieve at least a 20% reduction in acne scar area and various safety parameters, including injection site responses and changes in vital signs and laboratory values. The total study duration for each participant can be up to 420 days.

Researchers are collecting blood samples from adults who have cancer, are in cancer remission, have benign diseases such as diabetes or liver conditions, or are healthy volunteers. The study aims to evaluate specific DNA methylation markers in the blood to help detect various types of cancer and understand factors that may affect test results. Participants will provide whole blood, plasma, and serum samples that will be analyzed using a multi-analyte blood test designed to detect DNA methylation markers for cancer detection. The study will also investigate how benign conditions and substances like chemotherapy drugs might influence the tests accuracy. During the study, blood samples will be collected and examined to measure the tests sensitivity and specificity, check for interfering substances, and assess sample stability and reference ranges. Participants will be involved in providing blood samples within an 8-week period, and the main outcomes will be reviewed about one month after collection. The study is sponsored by Helio Genomics and is expected to complete in early 2028.

This research aims to compare the effects of two inhalers, budesonidealbuterol metered-dose inhaler BDA MDI and albuterol sulfate metered-dose inhaler AS MDI, both used as needed, in adolescents aged 12 to 17 years with asthma. The study focuses on their impact on the annual rate of severe asthma attacks in participants who have a documented diagnosis of asthma and at least one severe exacerbation in the past year. This is a randomized, double-blind, multicenter Phase IIIb trial. Participants are randomly assigned in equal numbers to receive either BDA MDI 160180 micrograms 2 puffs of 8090 micrograms or AS MDI 180 micrograms 2 puffs of 90 micrograms as needed, alongside their usual maintenance asthma therapy. The study includes a 7 to 28-day screening period, a 52-week treatment period, and a safety follow-up lasting 7 to 14 days after treatment ends. Additionally, a pharmacokinetic sub-study involves a single dose of open-label BDA MDI administered at a separate visit after safety follow-up. During the study, participants will be monitored through regular assessments including lung function tests such as peak expiratory flow, evaluation of asthma exacerbations, and safety checks for adverse events. The main outcome measured is the annualized rate of severe asthma exacerbations over the 52-week treatment. Safety follow-up and pharmacokinetic evaluations will further assess drug concentrations and participant well-being. Overall participation lasts from screening through safety monitoring after treatment completion.

Researchers are evaluating the Glide control strategy for upper limb prostheses in people with trans-radial unilateral limb loss. The study compares Glide, an experimental myoelectric control system using multiple EMG inputs, with the standard Direct Control DC prosthesis method. The goal is to assess whether Glide improves functional performance, satisfaction, and prosthesis usage over standard care in a clinical setting and during daily activities. Participants will use a single prosthesis system equipped to operate in both DC and Glide modes. The study follows a multiple baseline AB design over 24 weeks, where the A phase involves using the DC prosthesis for 10, 12, or 14 weeks, followed by the B phase using the Glide prosthesis for the remaining weeks. Prostheses are customized and fitted through multiple clinic visits, including occupational therapy training. Control modes are switched via an iPad app without hardware changes. Participants will attend several clinic visits for fitting, training, and assessments, completing questionnaires and functional tests such as CAPROQ, CAPPFUL, tBBT, FIT, DASH, and SAM at baseline, midpoints, crossover, and endpoint. Usage data like movement bouts and wear duration are recorded daily. The study includes weekly and periodic evaluations over the 24-week period, after which participants are refitted with their original prosthesis and receive further occupational therapy as needed.